Q3-26 revenue of $874.0 million, up 1.6% yoy; up 0.7% organically
Q3-26 non-GAAP operating margin of 16.3%, up 400 bps yoy
Q3-26 GAAP diluted Loss Per Share of $(0.81); Non-GAAP diluted EPS of $0.56, up 24.4%
Bruker Corporation (NASDAQ:BRKR) today announced it will report third quarter 2026 financial results before market opening on Wednesday, November 4, 2026. The Company will host a conference call and webcast at 8:30
Charité principal investigator Markus Ralser and colleagues discover and map 179,000 plasma proteoforms, revealing a vast molecular landscape for functional proteomics in biomedical research, drug discovery and
MultiDIA-PASEF significantly increases protein sequence coverage on timsUltra AIP
ProteoScape connects PASEF discovery with rapid prm-PASEF target validation
Spectronaut® AI transfer learning accelerates
New high-field NMR instrumentation strengthens biomolecular and materials science research at the UC Berkeley Pines Magnetic Resonance Center
Bruker Corporation (NASDAQ:BRKR) today announced a multi-system order from
Bruker Corporation (NASDAQ:BRKR) announced today that its senior leadership will present at the following conferences:
Wells Fargo 21st Annual Healthcare Conference in Boston, MA
Wednesday, September 9, 2026 at 8:00
RRP Preferred for High-Field Demonstration and First-of-a-Kind Power Plant OpportunitiesBruker Energy & Supercon Technologies (BEST), a segment of Bruker Corporation (NASDAQ:BRKR), and Luvata Materials &
Enables deeper integration of Atinary's SDLabs platform with Chemspeed automation, Bruker instruments and SciY software for closed-loop agentic AI-driven R&D
Bruker Corporation (NASDAQ:BRKR) today announced
MIMETAS’ unique organ-on-a-chip and human tissue models complement Bruker’s multiomics, NMR, spatial biology and preclinical imaging solutions
Bruker Corporation (NASDAQ:BRKR) today announced a majority investment in
Q2-26 Bruker Scientific Instruments (BSI) bookings up 10% organically year-over-year (yoy), with BSI book-to-bill >1.0x
Q2-26 revenue of $838.5 million, up +5.2% yoy; up 2.8% organically, or +3.4% excluding
Bruker Corporation (NASDAQ:BRKR) today announced it will report second quarter 2026 financial results before market opening on Tuesday, August 4, 2026. The Company will host a conference call and webcast at 9:00 a.m.
Bruker Corporation (NASDAQ:BRKR) today announced the acquisition of the DISQVER® clinical metagenomics platform from Noscendo GmbH.This press release features multimedia. View the full release here:
At ASM Microbe 2026, Bruker Corporation's (NASDAQ:BRKR) Microbiology & Infection Diagnostics (BMID) division is demonstrating its expanding portfolio and innovations across microbial identification, sepsis
At ASMS, Bruker Corporation (NASDAQ:BRKR) announced the launch of the new timsMRMS system, designed to empower researchers in petroleomics, sustainable fuels and advanced energy storage. The timsMRMS is an innovative
Bruker Also Launches Two Novel Mass Spectrometry Systems for Unique Applications in Energy Industry Research, and in Semiconductor Manufacturing
Launch of eXtreme 10M resolution novel timsMRMS™ mass
